ELOX · Insider Trading
Eloxx Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by ELOX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-21 | Geno J Germano | Director | A | +13,587 deriv. | — |
| 2026-06-17 | Domicilium Real Estate Fund III LP | 10%+ Owner | J | +600,000 | — |
| 2026-06-10 | Sumit Aggarwal | President and CEO | A | +328,833 deriv. | — |
| 2026-06-10 | Stephen W Webster | Director | A | +13,587 deriv. | — |
| 2026-06-10 | Nina S Kjellson | Director | A | +13,587 deriv. | — |
| 2026-06-10 | Alan Edmund Walts | Director | A | +8,590 deriv. | — |
| 2026-06-10 | Steven D Rubin | Director | A | +4,018 deriv. | — |
| 2026-06-05 | Domicilium Real Estate Fund III LP | 10%+ Owner | J | −113,636 | — |
| 2023-01-31 | Tomer Kariv | Director | A | +2,859 deriv. | — |
| 2023-01-31 | Lindsay Androski | Director | A | +2,859 deriv. | — |
| 2023-01-31 | Alan Edmund Walts | Director | A | +2,859 deriv. | — |
| 2023-01-31 | Steven D Rubin | Director | A | +2,859 deriv. | — |
| 2023-01-27 | Vijay Modur | HEAD OF R&D | A | +30,000 deriv. | — |
| 2023-01-27 | Sumit Aggarwal | PRESIDENT AND CEO | A | +68,700 deriv. | — |
| 2022-07-06 | Lindsay Androski | Director | A | +40,000 deriv. | — |
| 2022-06-17 | Jasbir Seehra | Director | A | +20,000 deriv. | — |
| 2022-06-17 | Gadi Veinrib | Director | A | +20,000 deriv. | — |
| 2022-06-17 | Rajesh B Parekh | Director | A | +20,000 deriv. | — |
| 2022-06-17 | Alan Edmund Walts | Director | A | +20,000 deriv. | — |
| 2022-06-17 | Steven D Rubin | Director | A | +20,000 deriv. | — |
| 2022-06-17 | Zafrira Avnur | Director | A | +20,000 deriv. | — |
| 2022-06-17 | Tomer Kariv | Director | A | +20,000 deriv. | — |
| 2022-06-17 | Ran Nussbaum | Director | A | +20,000 deriv. | — |
| 2021-12-03 | Vijay Modur | HEAD OF R&D | MIXED | +154,953 | −$46.35K |
| 2021-12-03 | Sumit Aggarwal | PRESIDENT AND CEO | MIXED | +197,225 | −$58.99K |
| 2021-12-03 | Alan Edmund Walts | Director | M | +37,695 | — |
| 2021-12-01 | Daniel E. Geffken | INTERIM CFO | Buy | +50,000 | +$36.00K |
| 2021-07-30 | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | MIXED | +1,104 | −$606 |
| 2021-05-26 | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | MIXED | +4,415 | −$2.55K |
| 2021-05-20 | Jasbir Seehra | Director | A | +20,000 deriv. | — |
| 2021-05-20 | Ran Nussbaum | Director | A | +20,000 deriv. | — |
| 2021-05-20 | Steven D Rubin | Director | A | +20,000 deriv. | — |
| 2021-05-20 | Zafrira Avnur | Director | A | +20,000 deriv. | — |
| 2021-05-20 | Alan Edmund Walts | Director | A | +3,334 deriv. | — |
| 2021-05-20 | Tomer Kariv | Director | A | +20,000 deriv. | — |
| 2021-05-20 | Gadi Veinrib | Director | A | +20,000 deriv. | — |
| 2021-05-20 | Rajesh B Parekh | Director | A | +3,334 deriv. | — |
| 2021-05-18 | Sumit Aggarwal | PRESIDENT AND CEO | A | +992,409 deriv. | — |
| 2021-05-18 | Vijay Modur | HEAD OF R&D | A | +496,204 deriv. | — |
| 2021-05-17 | Tomer Kariv | Director | Buy | +5,925,925 | +$8.00M |
| 2021-05-17 | Pontifax Management 4 G.P. (2015) Ltd. | 10%+ Owner | Buy | +29,629,625 | +$40.00M |
| 2021-05-17 | Rajesh B Parekh | Director | Buy | +2,466,666 | +$3.33M |
| 2021-05-17 | Ran Nussbaum | Director | Buy | +5,925,925 | +$8.00M |
| 2021-05-03 | Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | MIXED | +1,103 | −$1.00K |
| 2021-04-22 | Daniel E. Geffken | CHIEF FINANCIAL OFFICER | A | +100,000 deriv. | — |
| 2021-04-05 | Rajesh B Parekh | Director | A | +2,532,270 | — |
| 2021-04-02 | Alan Edmund Walts | Director | A | +77,695 deriv. | — |
| 2021-04-02 | Sumit Aggarwal | PRESIDENT AND CEO | A | +1,702,396 deriv. | — |
| 2021-04-02 | Vijay Modur | HEAD OF R&D | A | +930,945 deriv. | — |
| 2021-02-26 | Gregory C. Williams | CHIEF EXECUTIVE OFFICER | MIXED | +34,640 | −$60.67K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Domicilium Real Estate Fund III LP | 10%+ Owner | 14,285 | $188.13K |
| Sumit Aggarwal | President and CEO | 634 | $8.35K |
| Alan Edmund Walts | Director | 86 | $1.13K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ELOX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.